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Diabetes is now the most common single cause for the
need for real replacement therapy [1] and is associated
with increased cardiovascular risk. Indeed, the risk of dy-
ing from coronary artery disease is as high for those with
diabetes without prior myocardial infarction as it is for
those patients without diabetes with prior myocardial in-
farction [2].
The development of microalbuminuria and proteinuria
in diabetes is one of the earliest indicators not only of re-
nal disease but also of systemic vascular damage, and is as-
sociated with an excess of cardiovascular disease (CVD)
morbidity and mortality.
Increase in vascular risk occurs early in the protein-
uric condition in type 2 diabetes. Albumin excretion rates
(AER) >10 lg/min are associated with around 3 times the
risk of cardiovascular death. Furthermore, risk of heart
failure and cardiovascular death both increase with in-
creasing AER [3] and are greatest in those with more
rapidly progressive microalbuminuria [4].
In the World Health Organization Multinational Study
of Vascular Disease in Diabetes, both hypertension and
proteinuria carried a high mortality risk: 11- to 18-fold,
respectively, for men and women with type 1 diabetes,
18-fold for women with type 1 diabetes, and 5- to 8-fold,
respectively, for men and women with type 2 diabetes.
WHY ARE KIDNEY DISEASE AND CVD
ASSOCIATED?
The metabolic syndrome: A network of atherogenic
factors
Patients with microalbuminuria have many of the dele-
terious features associated with the metabolic syndrome
(Fig. 1); indeed, the presence of microalbuminuria is con-
sidered a component of the metabolic syndrome in the
World Health Organization criteria. In type 2 diabetes, of
course, features of the metabolic syndrome are present
Key words: .
C© 2005 by the International Society of Nephrology
usually in the prediabetic phase. In type 1 diabetes, fea-
tures often develop with the onset of microalbuminuria.
In the Third National Health and Nutrition Examination
Survey study, 34% of women and 42% of men with mi-
croalbuminuria had the metabolic syndrome [5].
In particular, insulin resistance, a greater degree of hy-
perglycemia, rising blood pressure with absence of noc-
turnal dip, greater endothelial dysfunction, and higher
C-reactive protein and sialic acid levels that suggest acti-
vation of the innate immune system are all seen in those
with microalbuminuria.
Similar lipid abnormalities also are seen with higher
concentrations of total cholesterol, very-low-density
lipoprotein cholesterol, low-density lipoprotein (LDL)
cholesterol, triglycerides, and fibrinogen (11% to 14%
higher in microalbuminuria and 26% to 87% higher in
macroalbuminuria in patients with type 1 diabetes [6]. In
addition, there is an increase in LDL mass and athero-
genic small dense LDL particles, which correlates with
plasma triglyceride concentrations. High-density lipopro-
tein levels also tend to be reduced with a disadvantageous
alteration in their composition [7, 8].
Familial predisposition
Positive family histories of hypertension or CVD in
parents without diabetes are related to the development
of albuminuria in the diabetic proband, emphasizing the
shared predisposition to these 2 conditions [9].
Smoking
In both type 1 and type 2 diabetes, smoking is an in-
dependent risk factor for the development of microal-
buminuria [10]. The association between smoking and
microalbuminuria is not strong, however, and it seems
unlikely that smoking explains much of the excess car-
diovascular risk.
Therefore, at least part of the increased cardiovascular
risk associated with microalbuminuria is related to dis-
advantageous alterations in conventional cardiovascular
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Fig. 1. The metablic syndrome: a network of atherogenic factors.
Adapted from McFarlane et al [21].
β-blocker Renin
Angiotensin-II
antagonist
Glomerulosclerosis
Na/fluid retention
Vasoconstriction
Vasodilation Antiproliferation
Degradation
products
ACE
inhibitor
Fig. 2. Role of the renin-angiotensin system
and sites of intervention.
risk factors, and to modify the risk treatment of these
factors remains the priority.
PREVENTION OF CVD IN THOSE WITH
DIABETIC KIDNEY DISEASE
Blood pressure reduction and inhibition of the
renin-angiotensin-aldosterone axis
In diabetes, effective blood pressure treatment is able
to lower AER and reduce the risk of progression to
macroalbuminuria. In the Appropriate Blood Pressure
Control in Diabetes Trial, intensive blood pressure con-
trol (mean, 128/75 mm Hg) was associated with reduced
progression from normoalbuminuria to microalbumin-
uria (P = 0.012) and microalbuminuria to overt albumin-
uria and less strokes [11].
A greater antiproteinuric effect is seen with inhibitors
of the renin-angiotensin system, even when declines in
blood pressure are similar. In the Microalbuminaria Re-
duction with Valsartan Study, angiotensin II antagonist
therapy resulted in a significantly greater decline in AER
when compared with calcium antagonist therapy despite
similar declines in both systolic and diastolic blood pres-
sure [12]. In the Irbesartan Microalbuminaria in Type 2
Diabetic Subjects Study, angiotensin II antagonist ther-
apy significantly reduced the progression from microal-
buminuria to overt diabetic proteinuria compared with
conventional therapy, with higher doses being more effi-
cacious than lower doses despite similar blood pressure
reductions [13].
The renin-angiotensin system plays a complex role in
the genesis of CVD beyond its effect on blood pressure
(Fig. 2); thus, agents that inhibit this system have impor-
tant cardiovascular as well as renal benefits. In type 2
diabetes in the Microalbuminuria, Cardiovascular, and
Renal Outcomes-Heart Outcomes Prevention Evalua-
tion substudy, treatment with an ACE inhibitor lowered
the risk of a primary combined end point of myocardial
infarction, stroke, or CVD death by 25% and total mortal-
ity by 24%, compared with conventional therapy despite
similar clinic blood pressures [14].
Angiotensin II antagonist therapy in 2 studies reduced
renal progression with a reduction in end-stage renal dis-
ease and hospitalization for heart failure [15].
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In studies where ACE inhibitors have been compared
with angiotensin II antagonists, there appears to be equiv-
alence between them, at least concerning lowering of
blood pressure and AER [16], and prevention of loss of
GFR [17].
A combination that appears particularly effective is
that of a diuretic with a renin-angiotensin system in-
hibitor. In the PREMIER Study, the combination of a
low-dose of thiazide with a low-dose ACE inhibitor low-
ered blood pressure and AER more than higher dose
of ACE inhibitor therapy alone. A future avenue of in-
terest is the benefit of aldosterone blockade, particularly
with the advent of newer aldosterone antagonists. Pa-
tients with type 2 diabetes and higher plasma aldosterone
levels, despite inhibition of the renin-aldosterone system,
tend to have worse albuminuria even with comparable
blood pressure which is lowered by the addition of low-
dose spironolactone (25 mg/day) [18].
Lipid-lowering therapy
In the recently published Collaborative Atorvastatin
Diabetes Study, primary prevention with statin therapy
reduced a primary end point of acute coronary heart dis-
ease events, coronary revascularization, or stroke by 37%
when compared with placebo in any patient with type 2
diabetes and a diabetic microvascular complication [19].
A multifactorial strategy combining glycemic therapy,
lipid lowering, blood pressure lowering, and aspirin re-
duced cardiovascular end points by 50% in patients with
type 2 diabetes and microalbuminuria [20].
CONCLUSION
Chronic kidney diseases, in particular diabetic kid-
ney disease, are associated with an excess all-cause and
cardiovascular mortality. The degree of proteinuria is a
marker of extra cardiovascular risk and therapies that re-
duce proteinuria to a greater extent, in particular ACE
inhibitor, and angiotensin II antagonist therapy carries
the most renal and cardiovascular protection. An aggres-
sive strategy of multirisk factor reduction is necessary,
including lipid lowering, smoking cessation, and blood
pressure reduction, as well as an ongoing search for new
effective strategies.
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